Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
600 | 600 | 14,505,965 | 1,615 | A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissol... | 1. A dissolvable-chewable tablet comprising:
a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C.; and one or more additives dispersed in the solid solution such that the at least one additive is released from the tablet when the ... | A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissol... | 1,600 |
601 | 601 | 15,119,883 | 1,613 | The present invention relates to an aqueous co-formulation of metalaxyl, which contains:
i. metalaxyl, in particular metalaxyl-M; ii. at least one organic pesticide compound PC1, which has a solubility in water of at most 1 g/l at 20° C. and a melting point in the range from 40 to 100° C.; and iii. an aqueous ... | 1-17. (canceled) 18. An aqueous co-formulation of metalaxyl comprising:
i. metalaxyl; ii. at least one organic pesticide compound PC1, which has a solubility in water of at most 1 g/l at 20° C. and a melting point in the range from 40 to 100° C.; and iii. an aqueous phase containing water and at least one surfactant; w... | The present invention relates to an aqueous co-formulation of metalaxyl, which contains:
i. metalaxyl, in particular metalaxyl-M; ii. at least one organic pesticide compound PC1, which has a solubility in water of at most 1 g/l at 20° C. and a melting point in the range from 40 to 100° C.; and iii. an aqueous ... | 1,600 |
602 | 602 | 15,169,498 | 1,634 | The present invention relates to methods for identifying variations that occur in the human genome and relating these variations to the genetic basis of disease and drug response. In particular, the present invention relates to identifying individual SNPs, determining SNP haplotype blocks and patterns, and, further, us... | 1-26. (canceled) 27. A system for genomic analysis to determine pharmacogenomic-related genetic loci without a priori knowledge of the location of said loci, the system comprising:
one or more databases that store information obtained from genotyping genomic DNA of individuals in a case population which comprises indiv... | The present invention relates to methods for identifying variations that occur in the human genome and relating these variations to the genetic basis of disease and drug response. In particular, the present invention relates to identifying individual SNPs, determining SNP haplotype blocks and patterns, and, further, us... | 1,600 |
603 | 603 | 15,104,698 | 1,617 | The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen. | 1. A matrix-type pharmaceutical tablet administrable by oral route once to twice per day with controlled release of baclofen by gastric retention, comprising granules of baclofen and one or more diluents within a matrix comprising at least a gelling agent, a gas-generating agent and a superdisintegrant. 2. The tablet a... | The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen.1. A matrix-type pharmaceutical tablet administrable by oral route once to twice per day with controlled release of baclofen by gastric retention, comprisin... | 1,600 |
604 | 604 | 13,000,241 | 1,611 | The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth. | 1. Co-mixture for the production of rapidly disintegrating tablets in a direct tableting process, consisting of 90-98 parts by weight of a sprayed mannitol and 10-2 parts by weight of a crosslinked sodium carboxymethylcellulose and characterised in that the co-mixture has a BET surface area of greater than 1.5 m2/g. 2.... | The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth.1. Co-mixture for the production of rapidly disintegrating tablets in a direct tableting process, consisting of 90-98 parts by weight of ... | 1,600 |
605 | 605 | 14,291,401 | 1,611 | Disclosed is a non-aqueous hair care composition comprising: a base oil being a volatile isoparaffin; a silicone elastomer; a solubilizer for the silicone elastomer which is a non-volatile silicone having a viscosity from about 25 to about 100,000 mm 2 ·s −1 . The composition of the present invention has improved stabi... | 1. A non-aqueous hair care composition comprising by weight:
(a) from about 50% to about 99.9% of a base oil being a volatile isoparaffin; (b) from about 0.025% to about 15% of a silicone elastomer; and (c) from about 1% to about 40% of a solubilizer for the silicone elastomer which is a non-volatile silicone having a ... | Disclosed is a non-aqueous hair care composition comprising: a base oil being a volatile isoparaffin; a silicone elastomer; a solubilizer for the silicone elastomer which is a non-volatile silicone having a viscosity from about 25 to about 100,000 mm 2 ·s −1 . The composition of the present invention has improved stabi... | 1,600 |
606 | 606 | 15,627,415 | 1,653 | The biological functionality of living microbial spores is modified using phenotypic engineering to endow the resulting modified spores with novel functionality that extends the usefulness of the spores for a variety of practical applications including, for example, sterility testing, the release of active compounds, a... | 1. A method of using engineered spores to test adequacy of a sterilization process for a system, comprising:
a) introducing the engineered spores into the system; b) sterilizing the system, wherein the system with the engineered spores is subjected to the sterilization process; c) exposing the engineered spores to a ge... | The biological functionality of living microbial spores is modified using phenotypic engineering to endow the resulting modified spores with novel functionality that extends the usefulness of the spores for a variety of practical applications including, for example, sterility testing, the release of active compounds, a... | 1,600 |
607 | 607 | 15,754,598 | 1,648 | A process for assaying viral vector manufactured by large-scale viral vector manufacturing processes to assure the resulting vector has acceptable purity and potency. The process entails three different types of assays, each one of which is optionally useful on a stand-alone basis, and which together provide the first ... | 1. An assay to determine the infectivity of a recombinant viral vector, the assay comprising:
a. obtaining a recombinant viral vector; and b. obtaining cells that support replication of said viral vector and then dividing said cells into a first cell culture and a second cell culture; and then c. contacting each of sai... | A process for assaying viral vector manufactured by large-scale viral vector manufacturing processes to assure the resulting vector has acceptable purity and potency. The process entails three different types of assays, each one of which is optionally useful on a stand-alone basis, and which together provide the first ... | 1,600 |
608 | 608 | 14,379,613 | 1,613 | Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one ... | 1-20. (canceled) 21. A composition comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles ... | Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one ... | 1,600 |
609 | 609 | 15,835,403 | 1,633 | The invention relates to the use of RNA and an aqueous injection buffer containing a sodium salt, a calcium salt and optionally a potassium salt and optionally lactate, in the preparation of a RNA injection solution for increasing RNA transfer and/or RNA translation into/in a host organism. The invention relates furthe... | 1-21. (canceled) 22. A method for increasing the expression of a mRNA in an organism comprising:
a) obtaining an aqueous mRNA injection solution comprising a calcium salt and a purified mRNA encoding a selected antigen, wherein said mRNA is capped and comprises a poly-A tail; and b) injecting the aqueous mRNA injection... | The invention relates to the use of RNA and an aqueous injection buffer containing a sodium salt, a calcium salt and optionally a potassium salt and optionally lactate, in the preparation of a RNA injection solution for increasing RNA transfer and/or RNA translation into/in a host organism. The invention relates furthe... | 1,600 |
610 | 610 | 12,920,524 | 1,639 | The present invention concerns a stable pharmaceutical solution, a process of the preparation thereof and therapeutic uses thereof. | 1. A stable solution of a pharmaceutical compound being an 2-oxo-1-pyrrolidine derivative of formula (I),
wherein,
R1 is C1-10 alkyl or C2-6 alkenyl;
R2 is C1-10 alkyl or C2-6 alkenyl;
X is —CONR4R5, —COOH, —COORS or —CN,
R3 is C1-10 alkyl;
R4 is hydrogen or C1-10 alkyl;
R5 is hydrogen or C1-10 alkyl,
charac... | The present invention concerns a stable pharmaceutical solution, a process of the preparation thereof and therapeutic uses thereof.1. A stable solution of a pharmaceutical compound being an 2-oxo-1-pyrrolidine derivative of formula (I),
wherein,
R1 is C1-10 alkyl or C2-6 alkenyl;
R2 is C1-10 alkyl or C2-6 alk... | 1,600 |
611 | 611 | 14,383,665 | 1,616 | The present invention relates to a liquid concentrate formulation comprising a pyripyropene pesticide of the formula I as defined below and an alkoxylated aliphatic alcohol as an adjuvant. Moreover, the invention relates to the use of the formulations for the treatment of plants and seed and to corresponding methods. | 1-29. (canceled) 30. A liquid concentrate formulation, which comprises
a) 0.5 to 30 wt %, based on the total weight of the formulation, of a compound of formula I;
b) 20 to 80 wt %, based on the total weight of the formulation, of an aromatic hydrocarbon solvent or aromatic hydrocarbon solvent mixture,
c) 10... | The present invention relates to a liquid concentrate formulation comprising a pyripyropene pesticide of the formula I as defined below and an alkoxylated aliphatic alcohol as an adjuvant. Moreover, the invention relates to the use of the formulations for the treatment of plants and seed and to corresponding methods.1-... | 1,600 |
612 | 612 | 14,372,088 | 1,641 | A method and composition for extracting an analyte from a test sample such as grain, so as to determine whether the test sample is contaminated with a toxin. The method is particularly useful for detecting the presence in a batch of grain of a mycotoxin, such as for example aflatoxin, ochratoxin, T2, zearalanone, vomit... | 1. A method for extracting one or more analytes from a dry test sample comprising the steps of:
a) mixing the sample with a composition comprising a proteinaceous material to form an admixture; b) providing conditions for the admixture to separate into a settled layer and a liquid layer, and c) collecting at least a po... | A method and composition for extracting an analyte from a test sample such as grain, so as to determine whether the test sample is contaminated with a toxin. The method is particularly useful for detecting the presence in a batch of grain of a mycotoxin, such as for example aflatoxin, ochratoxin, T2, zearalanone, vomit... | 1,600 |
613 | 613 | 15,986,592 | 1,617 | A hygiene product, a hygiene product pod, and a method of using the hygiene product pod, the hygiene product pod including a water soluble envelope and the hygiene product sealed in the envelope. The hygiene product includes a carrier comprising butylene glycol in an amount ranging from about 40 wt % to about 70 wt %, ... | 1-9. canceled 10. A single-use hygiene product pod comprising:
a water-soluble envelope; and a hygiene product sealed in the envelope, the hygiene product comprising: a carrier comprising butylene glycol in an amount ranging from about 25 wt % to about 70 wt %, based on the total weight of the hygiene product; and an a... | A hygiene product, a hygiene product pod, and a method of using the hygiene product pod, the hygiene product pod including a water soluble envelope and the hygiene product sealed in the envelope. The hygiene product includes a carrier comprising butylene glycol in an amount ranging from about 40 wt % to about 70 wt %, ... | 1,600 |
614 | 614 | 15,106,778 | 1,639 | A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof, and a pharmacologically accep... | 1. A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof, the composition comprising:
an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof; and a pharmacologically ... | A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof, and a pharmacologically accep... | 1,600 |
615 | 615 | 14,796,539 | 1,618 | A method of tracking immune cells to detect immune response. The method including steps of identifying a patient having a disease associated with an organ; administering biocompatible magnetic nanoparticles into the blood stream of the patient; and obtaining a magnetic resonance image of the organ. The presence of hype... | 1. A method of tracking immune cells, the method comprising:
identifying a patient having a disease associated with an organ; providing an aqueous suspension containing biocompatible magnetic nanoparticles, the aqueous suspension being free of particles having a size greater than 1000 nm, the biocompatible magnetic nan... | A method of tracking immune cells to detect immune response. The method including steps of identifying a patient having a disease associated with an organ; administering biocompatible magnetic nanoparticles into the blood stream of the patient; and obtaining a magnetic resonance image of the organ. The presence of hype... | 1,600 |
616 | 616 | 14,806,586 | 1,632 | Chemotherapeutic agents, methods of producing the chemotherapeutic agents, and methods of treating cancerous cells using the chemotherapeutic agents are provided herein. In an embodiment, a chemotherapeutic agent includes a chimeric gene comprising an anti-apoptotic Bcl-2 family promoter region and a pro-apoptotic Bcl-... | 1. A chemotherapeutic agent comprising:
a chimeric gene comprising an anti-apoptotic Bcl-2 family promoter region and a pro-apoptotic Bcl-2 family coding region. 2. The chemotherapeutic agent of claim 1, wherein the anti-apoptotic Bcl-2 family promoter region is chosen from Bcl-2 or Bcl-xL. 3. The chemotherapeutic agen... | Chemotherapeutic agents, methods of producing the chemotherapeutic agents, and methods of treating cancerous cells using the chemotherapeutic agents are provided herein. In an embodiment, a chemotherapeutic agent includes a chimeric gene comprising an anti-apoptotic Bcl-2 family promoter region and a pro-apoptotic Bcl-... | 1,600 |
617 | 617 | 15,534,450 | 1,648 | The present disclosure provides a rabies composition comprising IPRV and PIKA adjuvant, and the pharmaceutical use thereof. The present disclosure also discloses a method for prophylaxis or therapeutic treatment of rabies virus infection, the method comprises a step of administering the rabies vaccine composition to a ... | 1. A rabies vaccine composition, comprising:
a) inactivated purified rabies virus (IPRV), b) PIKA adjuvant, and c) human serum albumin (HSA);
wherein
the amount of IPRV is from 0.2 IU to 4.0 IU per unit dose,
the amount of PIKA adjuvant is from 250 μg to 5000 μg per unit dose, and
the amount of HSA is from 0.1% to 0.9... | The present disclosure provides a rabies composition comprising IPRV and PIKA adjuvant, and the pharmaceutical use thereof. The present disclosure also discloses a method for prophylaxis or therapeutic treatment of rabies virus infection, the method comprises a step of administering the rabies vaccine composition to a ... | 1,600 |
618 | 618 | 15,621,584 | 1,648 | Antibodies and method of making antibodies, either monoclonal or polyclonal wherein said antibodies have dual or multi-specific binding capacity to more than one type of antigenic epitope. The antibodies have simultaneous or independent recognition subsites to each of the epitopes. Antigenic epitopes include lipids, pe... | 1-54. (canceled) 55. A modified liposome comprising: a) one or more lipids found in a host cell plasma membrane lipid bilayer in a region of the lipid raft or one or more types of lipids normally found in HIV-1; b) an adjuvant, c) a protein or peptide epitope from HIV-1 virus and d) nef or nef with env antigens, wherei... | Antibodies and method of making antibodies, either monoclonal or polyclonal wherein said antibodies have dual or multi-specific binding capacity to more than one type of antigenic epitope. The antibodies have simultaneous or independent recognition subsites to each of the epitopes. Antigenic epitopes include lipids, pe... | 1,600 |
619 | 619 | 15,221,379 | 1,631 | The invention provides methods and systems of determining biopolymer profiles and correlations between structural units (residues) of a biopolymer based on sampling of the conformational space available to the molecule. The correlations between these structural units can further be used to find networks within a biopol... | 1. A method of engineering a variant of a biopolymer, wherein the biopolymer comprises a plurality of component structural units, the method comprising:
a) performing a simulation to calculate at least one trajectory for a plurality of geometric metrics using a three-dimensional atomic model of the biopolymer, wherein
... | The invention provides methods and systems of determining biopolymer profiles and correlations between structural units (residues) of a biopolymer based on sampling of the conformational space available to the molecule. The correlations between these structural units can further be used to find networks within a biopol... | 1,600 |
620 | 620 | 15,287,909 | 1,636 | The prior art largely suggests that immune competence in a cancer patient would destroy an antigenic viral vector before it transfects host cells with a transgene-rendering therapy futile. We surprisingly found the opposite is true: cancer patients with competent immune systems obtain the most therapeutic benefit from ... | 1. In a method of treating cancer in a human, the improvement comprising:
a. Determining the level of immunity against a viral vector, b. Confirming said human has a measurable level of immunity against said vector, and c. Administering to said human said viral vector. 2. The method of claim 1, wherein said administeri... | The prior art largely suggests that immune competence in a cancer patient would destroy an antigenic viral vector before it transfects host cells with a transgene-rendering therapy futile. We surprisingly found the opposite is true: cancer patients with competent immune systems obtain the most therapeutic benefit from ... | 1,600 |
621 | 621 | 14,415,434 | 1,617 | The present disclosure relates generally to crosslinked cation-binding polymers comprising monomers containing carboxylic acid groups and pKa decreasing groups, wherein the polymer contains i) calcium cations that are counterions to about 5% to about 75% of the carboxylic acid groups in the polymer; or ii) calcium cati... | 1. A crosslinked cation-binding polymer comprising:
a. monomers that comprise carboxylate groups and pKa decreasing groups; and b. calcium cations; wherein the calcium cations are counterions to about 5% to about 75% of the carboxylate groups in said polymer, and wherein the polymer optionally comprises no more than ab... | The present disclosure relates generally to crosslinked cation-binding polymers comprising monomers containing carboxylic acid groups and pKa decreasing groups, wherein the polymer contains i) calcium cations that are counterions to about 5% to about 75% of the carboxylic acid groups in the polymer; or ii) calcium cati... | 1,600 |
622 | 622 | 14,706,747 | 1,633 | Disclosed herein are methods and compositions for treating or preventing Huntington's Disease. | 1. A method of modifying a neuron in a subject with Huntington's Disease (HD), the method comprising administering a repressor of a mutant Htt (mHtt) allele to the subject such that the neuron is modified. 2. The method of claim 1, wherein the neuron is an HD neuron. 3. The method of claim 1, wherein the modification c... | Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.1. A method of modifying a neuron in a subject with Huntington's Disease (HD), the method comprising administering a repressor of a mutant Htt (mHtt) allele to the subject such that the neuron is modified. 2. The method of cla... | 1,600 |
623 | 623 | 14,640,318 | 1,642 | The present invention is directed to methods and compositions for modulating proteins involved in the immune response. The present invention further provides methods and compositions for treatment of autoimmune disease and cancer by modulating the expression and activity of such proteins. | 1. A method for the treatment of cancer, the method comprising administering to a subject in need thereof a combination of a pharmaceutically effective amount of (i) at least one immune checkpoint inhibitor and (ii) an inhibitor of Toso activity. 2. The method of claim 1, wherein the at least one immune checkpoint inhi... | The present invention is directed to methods and compositions for modulating proteins involved in the immune response. The present invention further provides methods and compositions for treatment of autoimmune disease and cancer by modulating the expression and activity of such proteins.1. A method for the treatment o... | 1,600 |
624 | 624 | 15,102,957 | 1,615 | Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent... | 1. A powder pharmaceutical composition comprising a) at least about 2% by weight of a PDE5 inhibitor or a pharmaceutically acceptable salt or ester thereof relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier. 2. The powder pharmaceutical compos... | Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent... | 1,600 |
625 | 625 | 15,791,677 | 1,628 | wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions. | 1. A compound comprising:
a) the basic skeleton of an organic compound having two to eight five and/or six-membered rings provided that the basic skeleton is not the basic skeleton of argentatin, betulinic acid, lanostane, oleanic acid, boswellic acid, glycyrrhetinic acid, ursolic acid, or tricyclic-bis-enone; b) a str... | wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.1. A compound comprising:
a) the basic skeleton of an organic... | 1,600 |
626 | 626 | 13,115,815 | 1,629 | A flavored oral care composition and method of making same for preventing and/or treating bacterial, fungal or inflammatory diseases and conditions of the oral cavity may be in the form of a rinse, spray, or the like, and free of glycerin and free of castor oil and castor oil derivatives, incorporates a chlorine dioxid... | 1. A flavored oral care single phase composition free of glycerin, castor oil and castor oil derivatives comprising:
(a) a source of chlorine dioxide; (b) a phosphate buffer; (c) a source of flavoring containing a polyoxyethylene sorbitan ester and a flavoring agent; (d) a sweetener; and (e) water. 2. The composition a... | A flavored oral care composition and method of making same for preventing and/or treating bacterial, fungal or inflammatory diseases and conditions of the oral cavity may be in the form of a rinse, spray, or the like, and free of glycerin and free of castor oil and castor oil derivatives, incorporates a chlorine dioxid... | 1,600 |
627 | 627 | 15,349,727 | 1,617 | Treatment of vaginal mycoses, bacterial vaginoses, and other forms of the vaginitis (inflammation of the vagina) by clinoptilolite having a particle size of between 0.2 and 10 μm. Clinoptilolite, when used externally, is effective in the treatment of these vaginal disorders in mammals and humans, and also for restoring... | 1-4. (canceled) 5. A method of treating vaginitis in a mammal, comprising applying a therapeutically effective amount of a pharmaceutically acceptable composition of clinoptilolite having a particle size of between 0.2 and 10 μm. 6. The method of claim 5, wherein applying the composition of clinoptilolite includes exte... | Treatment of vaginal mycoses, bacterial vaginoses, and other forms of the vaginitis (inflammation of the vagina) by clinoptilolite having a particle size of between 0.2 and 10 μm. Clinoptilolite, when used externally, is effective in the treatment of these vaginal disorders in mammals and humans, and also for restoring... | 1,600 |
628 | 628 | 14,105,662 | 1,653 | The present invention relates to a device and method for the detection of mastitis or other disease from a body fluid of a mammal for example from cow's milk. The device and method relates to a wedge microfluidic chamber for using a minimal amount of fluid and being able to use the device to observe leukocytes in a mon... | 1. A method for performing a leukocyte differential assay on a milk sample comprising:
a) adding a milk sample comprising live cells to a microfluidic chamber assembly comprising: i. a wedge base; and ii. a wedge top having a first top edge and an opposite second edge positioned on the base such that the second top edg... | The present invention relates to a device and method for the detection of mastitis or other disease from a body fluid of a mammal for example from cow's milk. The device and method relates to a wedge microfluidic chamber for using a minimal amount of fluid and being able to use the device to observe leukocytes in a mon... | 1,600 |
629 | 629 | 15,130,728 | 1,641 | A method for predicting risk of pre-eclampsia in a pregnant individual includes measuring one or more biochemical markers including an RBP4 biochemical marker in a blood sample obtained from the pregnant individual to determine one or more biomarker levels including an RBP4 biomarker level, identifying, for each of the... | 1. A method for predicting risk of pre-eclampsia in a pregnant individual, the method comprising:
measuring two or more biochemical markers including a retinol binding protein (RBP4) biochemical marker and a placental growth factor (PlGF) biochemical marker in a blood sample obtained from the pregnant individual to det... | A method for predicting risk of pre-eclampsia in a pregnant individual includes measuring one or more biochemical markers including an RBP4 biochemical marker in a blood sample obtained from the pregnant individual to determine one or more biomarker levels including an RBP4 biomarker level, identifying, for each of the... | 1,600 |
630 | 630 | 14,888,673 | 1,612 | Advantageously, para-chloroaniline (PCA) is minimal in antimicrobial articles prepared according to the method of the invention. A method of forming an antimicrobial article according to the invention comprises steps of: providing a polymerizable composition; incorporating an antimicrobially effective amount of at leas... | 1. A method of forming an antimicrobial article, the method comprising steps of:
providing a polymerizable composition; incorporating an antimicrobially effective amount of at least one chlorhexidine-containing antimicrobial agent into the polymerizable composition; and, polymerizing the polymerizable composition to fo... | Advantageously, para-chloroaniline (PCA) is minimal in antimicrobial articles prepared according to the method of the invention. A method of forming an antimicrobial article according to the invention comprises steps of: providing a polymerizable composition; incorporating an antimicrobially effective amount of at leas... | 1,600 |
631 | 631 | 13,612,925 | 1,662 | Provided are novel compositions for use in herbicide activity. Specifically, methods and compositions that modulate 5-enolpyruvylshikimate-3-phosphate synthase in plant species. The present invention also provides for combinations of compositions and methods that enhance weed control. | 1. A method of plant control comprising: treating a plant with a composition comprising a polynucleotide and a transfer agent, wherein said polynucleotide is essentially identical or essentially complementary to a portion of an EPSPS gene sequence or fragment thereof, or to a portion of an RNA transcript of said EPSPS ... | Provided are novel compositions for use in herbicide activity. Specifically, methods and compositions that modulate 5-enolpyruvylshikimate-3-phosphate synthase in plant species. The present invention also provides for combinations of compositions and methods that enhance weed control.1. A method of plant control compri... | 1,600 |
632 | 632 | 14,765,828 | 1,618 | A polymeric film includes a polymer matrix having at least one of a discrete RSNO adduct or a polymeric RSNO adduct associated therewith, by: covalent attachment to the polymer matrix; dispersion within the polymer matrix; or both, with the at least one of the discrete RSNO adduct or the polymeric RSNO adduct capable o... | 1. A polymeric film, comprising:
a polymer matrix having at least one of a discrete RSNO adduct or a polymeric RSNO adduct associated therewith, by: covalent attachment to the polymer matrix; dispersion within the polymer matrix; or both, with the at least one of the discrete RSNO adduct or the polymeric RSNO adduct ca... | A polymeric film includes a polymer matrix having at least one of a discrete RSNO adduct or a polymeric RSNO adduct associated therewith, by: covalent attachment to the polymer matrix; dispersion within the polymer matrix; or both, with the at least one of the discrete RSNO adduct or the polymeric RSNO adduct capable o... | 1,600 |
633 | 633 | 10,995,203 | 1,611 | A combination comprising creatine and/or creatinine and/or a derivative thereof and one or more retinoids. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way. | 1. An active substance combination comprising
(b) at least one of creatine, creatinine, a creatine derivative and a creatinine derivative, and (b) at least one retinoid. 2. The active substance combination of claim 1, wherein a weight ratio of creatinine to creatine is from about 10:1 to about 1:10. 3. The active sub... | A combination comprising creatine and/or creatinine and/or a derivative thereof and one or more retinoids. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.1. An active substance combination comprising
(b) at least one of ... | 1,600 |
634 | 634 | 15,591,301 | 1,653 | A method of producing jellyfish collagen extract by combining hard water, frozen jellyfish, protease enzymes, and sodium bisulfate to form a mixture. Heating the mixture for a period of time to permit the mixture to react. The filter, concentrate, and dry the mixture. | 1. A method of producing jellyfish collagen extract, comprising the steps of:
obtaining a quantity of frozen jellyfish; adding the frozen jellyfish to a tank containing hard water; adding protease enzymes and sodium bisulfate to the tank to form a mixture; heating the tank for a period of time that permits a reaction i... | A method of producing jellyfish collagen extract by combining hard water, frozen jellyfish, protease enzymes, and sodium bisulfate to form a mixture. Heating the mixture for a period of time to permit the mixture to react. The filter, concentrate, and dry the mixture.1. A method of producing jellyfish collagen extract,... | 1,600 |
635 | 635 | 13,852,654 | 1,615 | Disclosed is a hair conditioning composition comprising: a mono-alkyl amine cationic surfactant; a di-alkyl quaternized ammonium salt cationic surfactant; a high melting point fatty compound; a deposition polymer having specific monomers; a silicone compound; and an aqueous carrier. The composition of the present inven... | 1. A hair conditioning composition comprising by weight:
(a) from about 0.1% to about 8% of a mono-alkyl amine cationic surfactant which is a primary, secondary, and tertiary amines having one long alkyl or alkenyl group of from about 12 to about 30 carbon atoms; (b) from about 0.05% to about 6% of a di-alkyl quaterniz... | Disclosed is a hair conditioning composition comprising: a mono-alkyl amine cationic surfactant; a di-alkyl quaternized ammonium salt cationic surfactant; a high melting point fatty compound; a deposition polymer having specific monomers; a silicone compound; and an aqueous carrier. The composition of the present inven... | 1,600 |
636 | 636 | 13,612,929 | 1,662 | The present invention provides novel compositions for use to enhance weed control. Specifically, the present invention provides for methods and compositions that modulate acetolactate synthase in weed species. The present invention also provides for combinations of compositions and methods that enhance weed control. | 1. A method of plant control comprising: treating a plant with a composition comprising a polynucleotide and a transfer agent, wherein said polynucleotide is essentially identical or essentially complementary to an ALS gene sequence or fragment thereof, or to an RNA transcript of said ALS gene sequence or fragment ther... | The present invention provides novel compositions for use to enhance weed control. Specifically, the present invention provides for methods and compositions that modulate acetolactate synthase in weed species. The present invention also provides for combinations of compositions and methods that enhance weed control.1. ... | 1,600 |
637 | 637 | 14,971,343 | 1,619 | A cationic compatible metal oxide and oral care compositions containing the metal oxide are disclosed. Preferably, the oral care compositions contain a cationic compatible metal oxide and a cationic ingredient, such as for example, a cationic antibacterial agent such as cetyl pyridinium chloride (“CPC”). The cationic c... | 1-11. (canceled) 13. An oral care composition comprising
(1) an antibacterial effective amount of at least one cationic antibacterial agent; and (2) a cationic compatible metal oxide comprising a metal oxide particle having a negative surface charge and a vitamin molecule immobilized on the surface of the metal oxide p... | A cationic compatible metal oxide and oral care compositions containing the metal oxide are disclosed. Preferably, the oral care compositions contain a cationic compatible metal oxide and a cationic ingredient, such as for example, a cationic antibacterial agent such as cetyl pyridinium chloride (“CPC”). The cationic c... | 1,600 |
638 | 638 | 14,898,606 | 1,617 | Present invention relates to an aqueous oxidizing composition comprising at least one hydrophobic dye which provides improved mixing of such composition with an alkalizing composition prior to use and/or application such as onto hair. | 1. An aqueous emulsion composition comprising:
one or more oxidizing agent, one or both of: one or more fatty alcohol and one or more oil, one or more surfactant, and one or more dyestuff having a log P value at 25° C. of higher than or equal to 2, wherein the composition is free of solid peroxides or persulphates, or ... | Present invention relates to an aqueous oxidizing composition comprising at least one hydrophobic dye which provides improved mixing of such composition with an alkalizing composition prior to use and/or application such as onto hair.1. An aqueous emulsion composition comprising:
one or more oxidizing agent, one or bot... | 1,600 |
639 | 639 | 15,403,940 | 1,642 | A method of treating a malignancy in a human subject by analyzing pseudo-projection images of cells obtained from a sputum specimen obtained from a subject employs a biological specimen classifier that identifies cells from the sputum specimen as normal or abnormal. If abnormal cells are detected, then the abnormal cel... | 1. A method of treating a malignancy in a human subject comprising:
analyzing 3D images of cells based on pseudo-projections obtained from a sputum specimen obtained from a subject; operating a biological specimen classifier to identify cells from the sputum specimen as normal or abnormal; further classifying identifie... | A method of treating a malignancy in a human subject by analyzing pseudo-projection images of cells obtained from a sputum specimen obtained from a subject employs a biological specimen classifier that identifies cells from the sputum specimen as normal or abnormal. If abnormal cells are detected, then the abnormal cel... | 1,600 |
640 | 640 | 13,210,331 | 1,637 | Disclosed is a method for amplifying and detecting polynucleotides which can provide sensitive, specific detection of multiple targets from a clinical specimen within a relatively short time. | 1. A method comprising
amplifying one or more target nucleic acids using high-concentration target-specific primers in a first amplification reaction, thereby producing at least one nucleic acid amplicon containing at least one common primer binding site; rescuing the at least one nucleic acid amplicon; and amplifying ... | Disclosed is a method for amplifying and detecting polynucleotides which can provide sensitive, specific detection of multiple targets from a clinical specimen within a relatively short time.1. A method comprising
amplifying one or more target nucleic acids using high-concentration target-specific primers in a first am... | 1,600 |
641 | 641 | 15,381,638 | 1,651 | The present disclosure provides robust, high-throughput, and clinically applicable methods for simultaneously separating and quantifying the biologically active forms of Vitamin B1 (TPP) and Vitamin B6 (PLP) from human whole blood. | 1. A method of quantifying both native Thiamine Pyrophosphate (TPP) and native Pyridoxal 5-Phosphate (PLP) from a single sample of human whole blood using mass spectrometry, comprising:
eluting TPP and PLP at time of less than 20 seconds apart from one another from a liquid chromatography column; generating a mass spec... | The present disclosure provides robust, high-throughput, and clinically applicable methods for simultaneously separating and quantifying the biologically active forms of Vitamin B1 (TPP) and Vitamin B6 (PLP) from human whole blood.1. A method of quantifying both native Thiamine Pyrophosphate (TPP) and native Pyridoxal ... | 1,600 |
642 | 642 | 14,769,563 | 1,653 | The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or condit... | 1. A method for isolating stem cells comprising:
(a) Preparing a cell suspension from uterine cervix tissue, (b) Recovering the cells from said cell suspension, (c) Incubating said cells in a suitable cell culture medium and under conditions which allow cells to proliferate, and (d) Selecting the stem cells. 2. Method ... | The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or condit... | 1,600 |
643 | 643 | 14,537,463 | 1,644 | A method of comparative ligand mapping to identify peptide ligands presented by MHC positive cells that distinguish an infected/transfected cell from an uninfected/non-transfected cell is disclosed. | 1. A method for identifying at least one individual, endogenously loaded peptide ligand for an individual class I MHC molecule that distinguishes a transfected cell from a non-transfected cell, comprising the steps of:
culturing a non-transfected cell line and a transfected cell line, each containing a construct that e... | A method of comparative ligand mapping to identify peptide ligands presented by MHC positive cells that distinguish an infected/transfected cell from an uninfected/non-transfected cell is disclosed.1. A method for identifying at least one individual, endogenously loaded peptide ligand for an individual class I MHC mole... | 1,600 |
644 | 644 | 15,295,170 | 1,634 | The present disclosure describes the thermodynamic design and concentrations necessary to design probe compositions with desired optimal specificity that enable enrichment, detection, quantitation, purification, imaging, and amplification of rare-allele-bearing species of nucleic acids (prevalence <1%) in a large stoic... | 1. A nucleic acid detection composition comprising:
a target nucleic acid probe comprising a first target probe oligonucleotide and a second target probe oligonucleotide, wherein the first target probe oligonucleotide comprises a target probe complement region that is complementary to a target nucleic acid sequence, wh... | The present disclosure describes the thermodynamic design and concentrations necessary to design probe compositions with desired optimal specificity that enable enrichment, detection, quantitation, purification, imaging, and amplification of rare-allele-bearing species of nucleic acids (prevalence <1%) in a large stoic... | 1,600 |
645 | 645 | 15,702,462 | 1,613 | Magnetically driven biocompatible microrobots comprising a porous body having a magnetic layer and a biocompatible layer configured to carry and deliver cells to desired sites are described. Embodiments of microrobots are configured with enhanced cell-loading ability, such as by including a plurality of burr members di... | 1. A microrobot configured to be magnetically driven and biocompatible, the microrobot comprising:
a porous body having a three-dimensional structures; a plurality of burr members disposed on the porous body, wherein burr members of the plurality of burr members extend orthogonally from an outer surface of the porous b... | Magnetically driven biocompatible microrobots comprising a porous body having a magnetic layer and a biocompatible layer configured to carry and deliver cells to desired sites are described. Embodiments of microrobots are configured with enhanced cell-loading ability, such as by including a plurality of burr members di... | 1,600 |
646 | 646 | 16,278,008 | 1,656 | The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method f... | 1-22. (canceled) 23. A method for producing a biosensor for measuring glucose in a sample liquid comprising:
(i) obtaining a soluble flavin compound-binding glucose dehydrogenase secreted from an Aspergillus fungal body, which has enzymatic activity to glucose comprising catalyzing a reaction for oxidizing glucose in t... | The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method f... | 1,600 |
647 | 647 | 15,122,451 | 1,616 | The present invention relates to an emulsifiable or self-emulsifying liquid composition for plant growth control which contains cyanamide. | 1.-12. (canceled) 13. An emulsifiable or self-emulsifying liquid composition for regulating plant growth, comprising:
a) 5 to 50 wt. % cyanamide; b) 10 to 95 wt. % of a mixture of at least one oil and at least one organic solvent that is miscible with water; and, c) 0.1 to 10 wt. % of at least one emulsifier, wherein t... | The present invention relates to an emulsifiable or self-emulsifying liquid composition for plant growth control which contains cyanamide.1.-12. (canceled) 13. An emulsifiable or self-emulsifying liquid composition for regulating plant growth, comprising:
a) 5 to 50 wt. % cyanamide; b) 10 to 95 wt. % of a mixture of at... | 1,600 |
648 | 648 | 12,840,420 | 1,653 | The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expre... | 1. A method of obtaining a cell that has a desired potency for one or more of the following: (1) reduce leukocyte extravasation, (2) reduce leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) reduce Fut-7 expression, (4) reduce expression of CD15s on a leukocyte, the method comprising asses... | The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expre... | 1,600 |
649 | 649 | 13,464,452 | 1,631 | Computational methods are used to create cardiovascular simulations having desired hemodynamic features. Cardiovascular modeling methods produce descriptions of blood flow and pressure in the heart and vascular networks. Numerical methods optimize and solve nonlinear equations to find parameter values that result in de... | 1.-19. (canceled) 20. A system for determining cardiovascular information for a patient, the system comprising:
at least one computer system configured to:
receive patient-specific data regarding a geometry of an anatomical structure of the patient;
create, based on the patient-specific data, a three-dimensional model ... | Computational methods are used to create cardiovascular simulations having desired hemodynamic features. Cardiovascular modeling methods produce descriptions of blood flow and pressure in the heart and vascular networks. Numerical methods optimize and solve nonlinear equations to find parameter values that result in de... | 1,600 |
650 | 650 | 15,753,938 | 1,632 | This disclosure provides, among other things, a transgenic animal and a method of using the same to make antibodies that have a common light chain. In certain embodiments, the transgenic animal may comprising a genome comprising a common light chain transgene, wherein the common light chain transgene comprises a non-im... | 1. A transgenic animal comprising a genome comprising a common light chain transgene, wherein the common light chain transgene comprises a non-immunoglobulin light-chain promoter and a common light-chain coding sequence. 2. The transgenic animal of claim 1, wherein the common light chain is constitutively expressed. 3.... | This disclosure provides, among other things, a transgenic animal and a method of using the same to make antibodies that have a common light chain. In certain embodiments, the transgenic animal may comprising a genome comprising a common light chain transgene, wherein the common light chain transgene comprises a non-im... | 1,600 |
651 | 651 | 12,910,508 | 1,615 | The present invention relates to methods of protecting patients and sensitizing cancer cells in combination with chemotherapy and/or radiation therapy. More specifically, the invention provides nutritional methods and formulations that are capable of reducing cancer growth without causing chronic weight loss in patient... | 1. A method of alleviating cancer growth or a symptom of cancer, the method comprising:
a) identifying a patient with cancer; b) providing the patient with a first diet for a first predetermined period of time, the first diet providing the patient with at most 50% of the patient's normal caloric intake wherein at least... | The present invention relates to methods of protecting patients and sensitizing cancer cells in combination with chemotherapy and/or radiation therapy. More specifically, the invention provides nutritional methods and formulations that are capable of reducing cancer growth without causing chronic weight loss in patient... | 1,600 |
652 | 652 | 14,529,359 | 1,619 | A liquid dispensing razor including a reservoir containing a shave care composition. The shave care composition comprises water; one or more lipophilic skin conditioning agents; one or more thickening agents including electrolyte sensitive polymers; one or more emulsifying agents; and one or more lubricants. The shave ... | 1. A liquid dispensing razor including a reservoir containing a shave care composition, the shave care composition comprising:
water; one or more lipophilic skin conditioning agents; one or more thickening agents including electrolyte sensitive polymers; one or more emulsifying agents; and one or more lubricants. 2. Th... | A liquid dispensing razor including a reservoir containing a shave care composition. The shave care composition comprises water; one or more lipophilic skin conditioning agents; one or more thickening agents including electrolyte sensitive polymers; one or more emulsifying agents; and one or more lubricants. The shave ... | 1,600 |
653 | 653 | 14,786,456 | 1,626 | The present invention relates to a process for the preparation of a hydrogel suitable as carrier in a hydrogel-linked prodrug, to hydrogels obtainable from said process, the use of such hydrogel as a carrier in a hydrogel-linked prodrug and to hydrogel-linked prodrugs comprising a covalently conjugated hydrogel of the ... | 1. A process for the preparation of a hydrogel suitable as carrier in a hydrogel-linked prodrug comprising the steps of
(a) providing a hydrogel having groups Ax0, wherein groups Ax0 represent the same or different, preferably same, functional groups; (b) optionally covalently conjugating a spacer reagent of formula (I... | The present invention relates to a process for the preparation of a hydrogel suitable as carrier in a hydrogel-linked prodrug, to hydrogels obtainable from said process, the use of such hydrogel as a carrier in a hydrogel-linked prodrug and to hydrogel-linked prodrugs comprising a covalently conjugated hydrogel of the ... | 1,600 |
654 | 654 | 10,708,724 | 1,662 | The present invention relates to a novel culture system for generating transformed corn plants from mature seeds. In particular, the invention relates to the use of plant hormones during germination to affect the culture response. Transgenic corn plants can then be easily produced. | 1. A method of obtaining transformable callus tissue comprising:
germinating a mature seed in tissue culture media containing an effective amount of an auxin and an effective amount of a cytokinin to produce a growing seedling containing a nodal section; isolating the nodal section from the seedling; and culturing t... | The present invention relates to a novel culture system for generating transformed corn plants from mature seeds. In particular, the invention relates to the use of plant hormones during germination to affect the culture response. Transgenic corn plants can then be easily produced.1. A method of obtaining transformable... | 1,600 |
655 | 655 | 14,366,952 | 1,649 | The invention relates to methods for selectively quantifying A-beta aggregates, comprising the immobilization of anti-A-beta antibodies on a substrate, application of the sample to be tested onto the substrate, addition of probes labeled for detection, which mark these by specific binding to A-beta aggregates and detec... | 1.-27. (canceled) 28. A method for selectively quantifying and/or characterizing A-beta aggregates in a sample, which method comprises:
(a) applying a sample to be tested onto a substrate, (b) adding probes labeled for detection, which probes label A-beta aggregates by specifically binding to the aggregates, and (c) de... | The invention relates to methods for selectively quantifying A-beta aggregates, comprising the immobilization of anti-A-beta antibodies on a substrate, application of the sample to be tested onto the substrate, addition of probes labeled for detection, which mark these by specific binding to A-beta aggregates and detec... | 1,600 |
656 | 656 | 14,175,154 | 1,643 | Administering an amino acid-containing composition, containing the following amino acids (1)-(9), wherein
the molar content ratio of each amino acid to the total content of the amino acids (1)-(9) falls within the following numerical ranges: (1) leucine 35-66%; (2) isoleucine 5.0-15%; (3) valine 5.0-15%;... | 1. An amino acid-containing composition for enhancing recovery from muscle fatigue, comprising the following amino acids (1)-(9), wherein
the molar content ratio of each amino acid to the total content of said amino acids (1)-(9) falls within the following numerical ranges: (1) leucine 35-66%; (2) isoleucine 5.0-15%; (... | Administering an amino acid-containing composition, containing the following amino acids (1)-(9), wherein
the molar content ratio of each amino acid to the total content of the amino acids (1)-(9) falls within the following numerical ranges: (1) leucine 35-66%; (2) isoleucine 5.0-15%; (3) valine 5.0-15%;... | 1,600 |
657 | 657 | 14,821,072 | 1,613 | Methods of treatment using cadotril compositions are disclosed. | 1. A method for treating a subject experiencing diarrhea, comprising administering to the subject a composition comprising racecadotril, at least one surfactant, and a lipid, wherein said racecadotril achieves a maximum plasma concentration (Cmax) greater than about 300 ng/ml in said subject. 2. The method of claim 1, ... | Methods of treatment using cadotril compositions are disclosed.1. A method for treating a subject experiencing diarrhea, comprising administering to the subject a composition comprising racecadotril, at least one surfactant, and a lipid, wherein said racecadotril achieves a maximum plasma concentration (Cmax) greater t... | 1,600 |
658 | 658 | 15,343,570 | 1,628 | The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK). | 1. A method of treating or preventing cancer, comprising administering to a subject a therapeutically effective amount of a compound of formula I
wherein
X denotes CH or N,
R1 denotes NH2, CONH2 or H,
R2 denotes Hal, Ar1 or Het1,
R3 denotes NR5[C(R5)2]nHet2, NR5[C(R5)2]nCyc, Het2, O[C(R5)2]nAr2, NR5[C(R5)2]nA... | The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).1. A method of treating or preventing cancer, comprising administering to a subject a therapeutically effective amount of a compound of formula I
wherein
X d... | 1,600 |
659 | 659 | 15,475,114 | 1,616 | The method for preparing metal nanoparticles includes preparing an extract of myrrh and mixing the extract with an aqueous solution including a metal salt. The mixture changes in color from light yellow to dark brown upon formation of nanoparticles. The extract of myrrh can be a water extract prepared by, for example, ... | 1. A method of preparing metal nanoparticles from myrrh comprising:
preparing an extract of myrrh gum; providing an aqueous solution including a metal salt; and stirring the myrrh gum extract with the aqueous solution of the metal salt solution for about 15 to 20 minutes at a temperature of about 50° C. to about 100° C... | The method for preparing metal nanoparticles includes preparing an extract of myrrh and mixing the extract with an aqueous solution including a metal salt. The mixture changes in color from light yellow to dark brown upon formation of nanoparticles. The extract of myrrh can be a water extract prepared by, for example, ... | 1,600 |
660 | 660 | 12,937,818 | 1,618 | Pearlescent pigments including a largely transparent platelet-shaped substrate having a density ρ S and at least one optically active coating having a density ρ M , the substrate having an average size d 50 of 3 to 8 μm and an average height h S of 40 to 110 nm. The disclosure further relates to a method for produci... | 1. Pearlescent pigments comprising a largely transparent platelet-shaped substrate having a density ρS and at least one optically active coating having a density ρM,
wherein the substrate has an average size d50 of 3 to 8 μm and an average height hS of 40 to 110 nm. 2. The pearlescent pigments of claim 1,
wherein the a... | Pearlescent pigments including a largely transparent platelet-shaped substrate having a density ρ S and at least one optically active coating having a density ρ M , the substrate having an average size d 50 of 3 to 8 μm and an average height h S of 40 to 110 nm. The disclosure further relates to a method for produci... | 1,600 |
661 | 661 | 13,805,932 | 1,658 | Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in w... | 1. A method of administering tube feeding formulations comprising:
administering a first tube feed formulation having a whole food to a patient at a first time of a day corresponding to a typical breakfast time; administering a second tube feed formulation having a whole food to the patient at a second time of the day ... | Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in w... | 1,600 |
662 | 662 | 14,220,273 | 1,647 | The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc. | 1. A method of inhibiting degeneration of an extracellular matrix of a nucleus pulposus of an intervertebral disc having a degenerating nucleus pulposus and an annulus fibrosus in a patient in need thereof, comprising transdiscally administering into the degenerating nucleus pulposus an effective amount of a formulatio... | The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.1. A method of inhibiting degeneration of an extracellular matrix of a nucleus pulposus of an intervertebral disc having a degenerating nucleus pulposus and an annulus fibrosus in a patient in need ther... | 1,600 |
663 | 663 | 15,056,666 | 1,653 | The present invention is directed to a diagnostic composition for use in the viscoelastic analysis of a test liquid, and to a container ( 1 ) comprising same. The composition comprises at least an activator of coagulation, and at least one further constituent selected from CaCl 2 and from one or more inhibitors and/or... | 1. A diagnostic composition for use in the viscoelastic analysis of a test liquid, comprising at least two of the following constituents:
a) one activator of coagulation; and b) a calcium salt in an amount sufficient to ensure recalcification of the test liquid; or c) one inhibitors or other coagulation components or f... | The present invention is directed to a diagnostic composition for use in the viscoelastic analysis of a test liquid, and to a container ( 1 ) comprising same. The composition comprises at least an activator of coagulation, and at least one further constituent selected from CaCl 2 and from one or more inhibitors and/or... | 1,600 |
664 | 664 | 15,953,141 | 1,636 | The present invention relates to an artificially manipulated neovascularization-associated factor for regulating neovascularization and a use thereof. More particularly, the present invention relates to a system for artificially regulating neovascularization, which includes an artificially manipulated neovascularizatio... | 1. A composition for gene manipulation, comprising:
a guide nucleic acid capable of targeting at least one of the target sequence selected from SEQ ID NOs: 1 to 1522 in nucleic acid sequences of one or more genes selected from the group consisting of a VEGFA gene, an HIF1A gene, an ANGPT2 gene, an EPAS1 gene and an ANG... | The present invention relates to an artificially manipulated neovascularization-associated factor for regulating neovascularization and a use thereof. More particularly, the present invention relates to a system for artificially regulating neovascularization, which includes an artificially manipulated neovascularizatio... | 1,600 |
665 | 665 | 16,519,434 | 1,651 | Tributyrin and/or tributyrin derivatives are used to selectively increase the levels of Bifidobacteria in the gut. In preferred methods, the tributyrin and/or tributyrin derivatives are orally administered alone or in combination with a food item or other nutritionally acceptable carrier, and may further include Bifido... | 1. A method of increasing levels of Faecalibacterium prausnitzii in the gut of a human, the method comprising:
administering a tributyrin-containing composition to the human at a dosage of between 50 to 1,000 mg tributyrin or a tributyrin derivative per day; and wherein the tributyrin-containing composition is effectiv... | Tributyrin and/or tributyrin derivatives are used to selectively increase the levels of Bifidobacteria in the gut. In preferred methods, the tributyrin and/or tributyrin derivatives are orally administered alone or in combination with a food item or other nutritionally acceptable carrier, and may further include Bifido... | 1,600 |
666 | 666 | 14,895,076 | 1,641 | The invention relates to a method for establishing if a heart failure patient is susceptible to be hospitalized and/or rehospitalized, wherein said method comprises measuring the concentration of IGFBP 2 in a sample obtained from said heart failure patient. | 1. A method for establishing if a heart failure patient is susceptible to be hospitalized and/or rehospitalized, wherein said method comprises
measuring the concentration of IGFBP2 in a sample obtained from said heart failure patient, and selecting a patient for hospitalization or rehospitalization based on the concent... | The invention relates to a method for establishing if a heart failure patient is susceptible to be hospitalized and/or rehospitalized, wherein said method comprises measuring the concentration of IGFBP 2 in a sample obtained from said heart failure patient.1. A method for establishing if a heart failure patient is sus... | 1,600 |
667 | 667 | 14,322,827 | 1,656 | The disclosure relates to the field of glyco-engineering, more specifically, to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular, without the need for adding an extra enzyme. ... | 1. A eukaryotic cell comprising:
a first exogenous polynucleotide encoding an endoglucosaminidase enzyme; and a second exogenous polynucleotide encoding a glycoprotein. 2. The eukaryotic cell of claim 1, which does not express an endogenous endoglucosaminidase enzyme. 3. The eukaryotic cell of claim 1, which is selecte... | The disclosure relates to the field of glyco-engineering, more specifically, to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular, without the need for adding an extra enzyme. ... | 1,600 |
668 | 668 | 15,024,265 | 1,618 | Disclosed is an ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system including gas microbubbles, emulsion microdroplets and clusters thereof. Also, disclosed are a cluster composition and a pharmaceutical comp... | 1. A cluster composition which comprises a suspension of clusters in an aqueous biocompatible medium, wherein said clusters have a diameter in the range of 1 to 10 μm, and a circularity of <0.9 and comprises:
(i) a first component which comprises a gas microbubble and a first stabilizer to stabilize said gas microbubbl... | Disclosed is an ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system including gas microbubbles, emulsion microdroplets and clusters thereof. Also, disclosed are a cluster composition and a pharmaceutical comp... | 1,600 |
669 | 669 | 15,423,887 | 1,612 | The present invention concerns an orodispersible self-supporting film free from hydrocolloids comprising:
a) a film-forming substance consisting of a maltodextrin in an amount comprised between 40 and 80% by weight; b) one or more plasticizer in a total amount comprised between 15 and 55% by weight; e) a s... | 1. An orodispersible self-supporting film free from hydrocolloids comprising:
a) a film-forming substance consisting of a maltodextrin in an amount between 40 and 80% by weight; b) one or more plasticizer in a total amount comprised between 15 and 55% by weight; e) one or more surfactant system in an amount comprised b... | The present invention concerns an orodispersible self-supporting film free from hydrocolloids comprising:
a) a film-forming substance consisting of a maltodextrin in an amount comprised between 40 and 80% by weight; b) one or more plasticizer in a total amount comprised between 15 and 55% by weight; e) a s... | 1,600 |
670 | 670 | 15,217,333 | 1,651 | The present invention relates generally to methods and compositions useful for application to skin and hair comprising saccharide isomerate, Alteromonas ferment extract, and a dermatologically acceptable vehicle, wherein the composition is capable of moisturizing and/or improving the appearance and/or condition of sk... | 1. A method of treating a subject in need thereof comprising applying a topical composition comprising saccharide isomerate, Alteromonas ferment extract, and a dermatologically acceptable vehicle to skin, wherein at least one of filaggrin production is increased, skin moisture is increased, occludin production is incre... | The present invention relates generally to methods and compositions useful for application to skin and hair comprising saccharide isomerate, Alteromonas ferment extract, and a dermatologically acceptable vehicle, wherein the composition is capable of moisturizing and/or improving the appearance and/or condition of sk... | 1,600 |
671 | 671 | 14,430,875 | 1,644 | The present invention provides a method for polyclonal stimulation of T cells, the method comprising contacting a population of T cells with a nanomatrix, the nanomatrix comprising a) a matrix of mobile polymer chains, and b) attached to said matrix of mobile polymer chains one or more stimulatory agents which provide ... | 1. The use of a nanomatrix for in-vitro polyclonal stimulation of T cells, the nanomatrix comprising
a) a matrix of mobile polymer chains, and b) attached to said matrix of mobile polymer chains one or more stimulatory agents which provide activation signals to the T cells; wherein the nanomatrix is 1 to 500 nm in size... | The present invention provides a method for polyclonal stimulation of T cells, the method comprising contacting a population of T cells with a nanomatrix, the nanomatrix comprising a) a matrix of mobile polymer chains, and b) attached to said matrix of mobile polymer chains one or more stimulatory agents which provide ... | 1,600 |
672 | 672 | 14,649,421 | 1,631 | Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether pat... | 1. A method for predicting a subject's responsiveness to an anti-angiogenic therapeutic agent comprising:
obtaining a test sample from a subject; measuring expression levels of a biomarker panel from the test sample obtained from the subject, wherein the biomarker panel comprises one or more biomarkers selected from Ta... | Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether pat... | 1,600 |
673 | 673 | 15,134,112 | 1,618 | Described herein are single and dual modality bisphosphonate conjugated imaging probes. Also described herein are methods of synthesizing and using the single and dual modality bisphosphonate conjugated imaging probes. | 1. An imaging probe comprising:
a bisphosphonate; and a positron emission tomography (PET) radionuclide, wherein the PET radionuclide is conjugated to the bisphosphonate. 2. The imaging probe of claim 1, wherein the PET radionuclide is directly conjugated to the bisphosphonate via N-succinimidyl-4-[18F]fluorobenzoate a... | Described herein are single and dual modality bisphosphonate conjugated imaging probes. Also described herein are methods of synthesizing and using the single and dual modality bisphosphonate conjugated imaging probes.1. An imaging probe comprising:
a bisphosphonate; and a positron emission tomography (PET) radionuclid... | 1,600 |
674 | 674 | 15,569,552 | 1,653 | The present disclosure provides a culture device for enumerating colonies of microorganisms. The device can comprise a base, a coversheet, and a nonporous spacer member disposed therebetween. The spacer member comprises an aperture that defines a growth compartment. At least one adhesive layer adhered to the base or th... | 1. A culture device for enumerating colonies of microorganisms, the device comprising:
a base having opposing inner and outer surfaces; a coversheet having opposing inner and outer surfaces; a spacer member disposed between the base and the cover sheet, wherein the spacer member is coupled to the base or the coversheet... | The present disclosure provides a culture device for enumerating colonies of microorganisms. The device can comprise a base, a coversheet, and a nonporous spacer member disposed therebetween. The spacer member comprises an aperture that defines a growth compartment. At least one adhesive layer adhered to the base or th... | 1,600 |
675 | 675 | 15,031,141 | 1,618 | The present disclosure is directed to methods and a diagnostic kit for producing pericyte information from a subject for identifying and/or treating a subject condition. In one aspect, a method for identifying a subject condition is provided. The method includes administering intravenously to a subject an effective amo... | 1. A method for identifying a subject condition, the method comprising:
administering intravenously to a subject an effective amount of an injectable solution comprising fluorescent markers to selectively label a plurality of pericytes in the subject's body; acquiring, using an imaging system, fluorescence signals orig... | The present disclosure is directed to methods and a diagnostic kit for producing pericyte information from a subject for identifying and/or treating a subject condition. In one aspect, a method for identifying a subject condition is provided. The method includes administering intravenously to a subject an effective amo... | 1,600 |
676 | 676 | 11,885,716 | 1,611 | A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. | 1. A method for producing a transdermal therapeutic system, comprising the steps of:
providing an active substance-impermeable carrier layer or an optionally present reservoir layer or matrix layer with a fibre-free pressure-sensitive adhesive layer; by a printing method, applying individually dosed portions of a flowa... | A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system.1. A method for prod... | 1,600 |
677 | 677 | 13,956,744 | 1,617 | Achieving enhanced scent expression in antiperspirant compositions and methods. | 1) A method of enhancing fragrance expression, comprising formulating an antiperspirant composition so that no more than 25% by weight of the composition, of the non-perfume and non-antiperspirant active ingredients, have a polarity between 3 MPa1/2 and 15 MPa1/2. 2) The method of claim 1, wherein the composition compr... | Achieving enhanced scent expression in antiperspirant compositions and methods.1) A method of enhancing fragrance expression, comprising formulating an antiperspirant composition so that no more than 25% by weight of the composition, of the non-perfume and non-antiperspirant active ingredients, have a polarity between ... | 1,600 |
678 | 678 | 15,323,736 | 1,627 | Disclosed herein is an aqueous tissue clearing solution for making a biological material, such as a tissue or an organ of an animal, or a bio-engineered collagen scaffold transparent. | 1. An aqueous solution for rendering a biomaterial transparent, comprising:
a first active compound of formula (I)
or
a second active compound of formula (II)
or a combination thereof;
a sufficient amount of a solvent that is water or a salt balanced buffer solution for dissolving the first or se... | Disclosed herein is an aqueous tissue clearing solution for making a biological material, such as a tissue or an organ of an animal, or a bio-engineered collagen scaffold transparent.1. An aqueous solution for rendering a biomaterial transparent, comprising:
a first active compound of formula (I)
or
a secon... | 1,600 |
679 | 679 | 15,599,399 | 1,658 | A wound dressing composition comprising a chitosan and an oxidized cellulose. For example, the composition may be in the form of a sponge formed by freeze drying an aqueous dispersion of chitosan and oxidized regenerated cellulose (ORC). The composition is especially suitable for the treatment of chronic wounds. | 1. A wound dressing composition comprising a chitosan and an oxidized cellulose. 2. The wound dressing composition of claim 1, wherein the chitosan and the oxidized cellulose are intimately mixed in the wound dressing composition. 3. The wound dressing composition of claim 1, wherein the oxidized cellulose is in the fo... | A wound dressing composition comprising a chitosan and an oxidized cellulose. For example, the composition may be in the form of a sponge formed by freeze drying an aqueous dispersion of chitosan and oxidized regenerated cellulose (ORC). The composition is especially suitable for the treatment of chronic wounds.1. A wo... | 1,600 |
680 | 680 | 13,321,723 | 1,631 | A method ( 10 ) for forming novel signatures of biological data is provided. The method comprises ranking features based on a trend value, which is created based on multiple signatures identified by a pattern discovery method. Furthermore, a device ( 30 ) and a computer program product ( 40 ), performing the steps acco... | 1. A method (10) for forming novel signatures of biological data comprising a number of features (F={F1, F2, . . . , Fn}) based on analyzing a set of multiple signatures of biological data, said method comprising the steps of:
obtaining (110) a set of multiple signatures of biological data by running a feature subset s... | A method ( 10 ) for forming novel signatures of biological data is provided. The method comprises ranking features based on a trend value, which is created based on multiple signatures identified by a pattern discovery method. Furthermore, a device ( 30 ) and a computer program product ( 40 ), performing the steps acco... | 1,600 |
681 | 681 | 14,430,255 | 1,612 | The present invention concerns an orodispersible self-supporting film free from hydrocolloids comprising: a) a film-forming substance consisting of a maltodextrin in an amount comprised between 40 and 80% by weight; b) a plasticizer in an amount comprised between 15 and 55% by weight; e) a surfactant System in an amoun... | 1. An orodispersible self-supporting film free from hydrocolloids comprising:
a) a film-forming substance consisting of a maltodextrin in an amount between 40 and 80% by weight; b) a plasticizer in an amount comprised between 15 and 55% by weight; e) a surfactant system in an amount comprised between 0.5 and 6% by weig... | The present invention concerns an orodispersible self-supporting film free from hydrocolloids comprising: a) a film-forming substance consisting of a maltodextrin in an amount comprised between 40 and 80% by weight; b) a plasticizer in an amount comprised between 15 and 55% by weight; e) a surfactant System in an amoun... | 1,600 |
682 | 682 | 15,273,276 | 1,627 | A topical composition for treating fungal skin infections with associated inflammation may include making or administering to the affected skin area an antifungal and steroid, such as a corticosteroid. Certain compositions may include antifungals such as itraconazole or econazole and corticosteroids such as fluticasone... | 1. A method of compounding a topical composition for treating a fungal skin condition and associated inflammation, the method comprising:
combining (a) fluticasone, or pharmaceutically acceptable salt, ester, or derivative thereof, (b) itraconazole, or pharmaceutically acceptable salt, ester, or derivative thereof, (c)... | A topical composition for treating fungal skin infections with associated inflammation may include making or administering to the affected skin area an antifungal and steroid, such as a corticosteroid. Certain compositions may include antifungals such as itraconazole or econazole and corticosteroids such as fluticasone... | 1,600 |
683 | 683 | 16,053,537 | 1,625 | The invention provides synthetic methods and synthetic intermediates that are useful for preparing the antibacterial compound: | 1. The compound: 2. A method for preparing the compound:
comprising, converting an amide of the formula:
to the compound. 3. A method for preparing the compound:
comprising, converting a chloride of the formula:
to the compound. | The invention provides synthetic methods and synthetic intermediates that are useful for preparing the antibacterial compound:1. The compound: 2. A method for preparing the compound:
comprising, converting an amide of the formula:
to the compound. 3. A method for preparing the compound:
... | 1,600 |
684 | 684 | 12,598,703 | 1,613 | The present invention relates to specific synergistic active antimicrobial compositions for hygiene disinfectant products like antimicrobial liquid or solid soaps, disinfectant cleansing solutions and disinfectant emulsions for the treatment of skin surface, specifically for the treatment of hand surface and/or for the... | 1. A cosmetic, pharmaceutical and/or household product preparation, comprising a mixture comprising or consisting of
a) an antimicrobial active amount of 1,2-decanediol of formula 1:
and
b) an antimicrobial active amount of one or more compounds selected from the group consisting of ethanol, propan-1-ol, pro... | The present invention relates to specific synergistic active antimicrobial compositions for hygiene disinfectant products like antimicrobial liquid or solid soaps, disinfectant cleansing solutions and disinfectant emulsions for the treatment of skin surface, specifically for the treatment of hand surface and/or for the... | 1,600 |
685 | 685 | 15,350,506 | 1,632 | Disclosed herein are devices for detecting presence and/or amount of an analyte, such as glucose, in a urine sample when diluted in a toilet bowl containing water and methods of using same. The disclosed devices eliminate the need to handle urine samples or a device that has been contacted with a urine sample, and can ... | 1. A method of detecting glucose in urine of a diabetic subject taking an amount of a sodium glucose cotransporter 2 (SGLT2) inhibitor, the method comprising:
placing in a toilet bowl containing water a device that comprises an absorbent substrate having one or more reagents in an amount sufficient to react with glucos... | Disclosed herein are devices for detecting presence and/or amount of an analyte, such as glucose, in a urine sample when diluted in a toilet bowl containing water and methods of using same. The disclosed devices eliminate the need to handle urine samples or a device that has been contacted with a urine sample, and can ... | 1,600 |
686 | 686 | 14,979,263 | 1,612 | The invention relates to photocurable compositions comprising at least one dispersion of acrylic polymer particles. | 1. A nail composition comprising at least one photocrosslinkable compound, at least one photoinitiator and at least one dispersion of acrylic polymer particles, wherein the composition is photocurable, and wherein the at least one dispersion of acrylic polymer particles comprises particles of a C1-C4 alkyl (meth)acryla... | The invention relates to photocurable compositions comprising at least one dispersion of acrylic polymer particles.1. A nail composition comprising at least one photocrosslinkable compound, at least one photoinitiator and at least one dispersion of acrylic polymer particles, wherein the composition is photocurable, and... | 1,600 |
687 | 687 | 14,910,577 | 1,662 | The present invention provides wheat grain comprising (1,3;1,4)-β-D-glucan (BG). The wheat grain is characterised by one or more of the following features; a BG content of at least 3% (w/w); the BG of the grain has a DP3/DP4 ratio between about 1.0 and about 2.0 or between about 1.0 and 2.3; and the BG is partially wat... | 1. Wheat grain comprising (1,3;1,4)-β-D-glucan (BG), which is characterised by one or more or all of:
a) wherein the BG content of the grain is at least 3% (w/w);
b) wherein the BG of the grain has a DP3/DP4 ratio between about 1.0 and about 2.0 or between about 1.0 and 2.3; and
c) wherein the BG is partially water sol... | The present invention provides wheat grain comprising (1,3;1,4)-β-D-glucan (BG). The wheat grain is characterised by one or more of the following features; a BG content of at least 3% (w/w); the BG of the grain has a DP3/DP4 ratio between about 1.0 and about 2.0 or between about 1.0 and 2.3; and the BG is partially wat... | 1,600 |
688 | 688 | 14,039,114 | 1,611 | The invention provides for a method of treating inappetance-induced weight loss in one or more companion animals or livestock. The method provides for administering a therapeutically effective amount of a capromorelin-containing composition to the companion animal or livestock. Optionally, one or more flavoring agents ... | 1. A method of treating inappetance in a companion animal, comprising the step of administering a therapeutically effective amount of a capromorelin-containing composition to the companion animal. 2. The method of claim 1, wherein the therapeutically effective amount of the capromorelin-containing composition is orally... | The invention provides for a method of treating inappetance-induced weight loss in one or more companion animals or livestock. The method provides for administering a therapeutically effective amount of a capromorelin-containing composition to the companion animal or livestock. Optionally, one or more flavoring agents ... | 1,600 |
689 | 689 | 14,785,400 | 1,631 | The present application relates to a method for determining a risk score that indicates a risk that a clinical event will occur within a certain period of time. The risk score is based at least in part on a combination of inferred activities of two or more cellular signaling pathways in a tissue and/or cells and/or a b... | 1. A method comprising:
inferring activity of two or more cellular signaling pathways in a tissue and/or cells and/or a body fluid of a subject based at least on the expression levels (20) of one or more target gene(s) of the cellular signaling pathways measured in an extracted sample of the tissue and/or the cells and... | The present application relates to a method for determining a risk score that indicates a risk that a clinical event will occur within a certain period of time. The risk score is based at least in part on a combination of inferred activities of two or more cellular signaling pathways in a tissue and/or cells and/or a b... | 1,600 |
690 | 690 | 13,467,414 | 1,628 | The use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both is provided. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 1. A pharmaceutical, nutraceutical, food supplement or food composition comprising 25-OH D3 in an amount sufficent to increase or retain or prevent the loss of muscle function or muscle strength in a human. 2. A composition according to claim 1 wherein the amounts are sufficient to increase muscle strength in a patient... | The use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both is provided. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.1. A pharmaceutical, ... | 1,600 |
691 | 691 | 14,362,503 | 1,611 | The present invention relates to a method of disinfecting a surface and to an antimicrobial composition. Essential oils, which are used as antimicrobial actives, are also known for their strong odour; using high amounts of these gives a strong smell to the product that is not always appreciated by the consumer. It is t... | 1. An antimicrobial composition comprising
(a) 0.01 to 2% of an essential oil active mixture of 0.02% to 0.2% thymol and 0.05% to 0.5% terpineol; and (b) 0.1% to 5% of a hydrotrope selected from the group consisting of sodium benzoate, sodium toluene sulphonate, sodium cumene sulphonate, sodium xylene sulphonate, sodiu... | The present invention relates to a method of disinfecting a surface and to an antimicrobial composition. Essential oils, which are used as antimicrobial actives, are also known for their strong odour; using high amounts of these gives a strong smell to the product that is not always appreciated by the consumer. It is t... | 1,600 |
692 | 692 | 15,555,752 | 1,634 | The present application relates to the field of cancer, particular to hypoxic tumors. It was found that hypoxia is an important driver for hypermethylation of (promoters of) tumor suppressor genes. As this hypermethylation is a stable signature that is also present in circulating tumor DNA in peripheral blood, detectin... | 1-7. (canceled) 8. A method of determining tumor hypoxia via detecting hypermethylation in a cancer patient, comprising:
obtaining from a subject a tissue sample comprising circulating tumor DNA, wherein the circulating tumor DNA comprises one or more promoters of tumor suppressor genes; detecting whether methylation s... | The present application relates to the field of cancer, particular to hypoxic tumors. It was found that hypoxia is an important driver for hypermethylation of (promoters of) tumor suppressor genes. As this hypermethylation is a stable signature that is also present in circulating tumor DNA in peripheral blood, detectin... | 1,600 |
693 | 693 | 15,968,456 | 1,623 | wherein X is Cl or Br. A compound isolated from Actinomadura and having a chemical formula of C43H69ClN4O10S2 or C43H69BrN4O10S2 is also provided. Compositions including the compounds and methods of using the compounds to treat fungal infections including those such as Candida are also disclosed. | 1. A pharmaceutical composition comprising an effective amount of a compound of Formula I:
or pharmaceutically acceptable salt thereof for treating a fungal infection in a mammal, wherein X is Cl or Br; and
a pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1, formulated for ora... | wherein X is Cl or Br. A compound isolated from Actinomadura and having a chemical formula of C43H69ClN4O10S2 or C43H69BrN4O10S2 is also provided. Compositions including the compounds and methods of using the compounds to treat fungal infections including those such as Candida are also disclosed.1. A pharmaceutical com... | 1,600 |
694 | 694 | 15,436,404 | 1,651 | Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provide... | 1: A composition suitable for oral administration to an animal comprising an immune stress-reducing enzyme in an orally acceptable carrier, wherein said composition is selected from the group consisting of:
(i) an animal feed comprising an amount of said enzyme effective to decrease the level of positive acute phase pr... | Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provide... | 1,600 |
695 | 695 | 15,238,014 | 1,655 | The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated ... | 1. A process for preparing an L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia):
comprising the following steps:
a) hydrolyzing a compound of Formula (IIk):
wherein R3 is C1-C6 alkyl; in the presence of i... | The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated ... | 1,600 |
696 | 696 | 15,301,347 | 1,627 | The present invention relates to the use of compounds of the formula (I)
in which R 1 , R 2 , R 3 , n, X and Y have the meanings given in the description, for controlling animal pests, in particular insects and/or spider mites a... | 1. A method of using one or more N-arylamidine-substituted trifluoroethyl sulphoxide derivatives of formula (I)
where
n represents the number 0 or 1,
X, Y independently of one another
represent hydrogen, fluorine, chlorine, bromine, iodine, (C1-C4)-alkyl, (C1-C4)-haloalkyl, (C1-C4)-alkoxy, (C1-C4)-haloalkoxy ... | The present invention relates to the use of compounds of the formula (I)
in which R 1 , R 2 , R 3 , n, X and Y have the meanings given in the description, for controlling animal pests, in particular insects and/or spider mites a... | 1,600 |
697 | 697 | 13,983,651 | 1,631 | The present invention relates to a method for stratifying a patient into a clinically relevant group comprising the identification of the probability of an alteration within one or more sets of molecular data from a patient sample in comparison to a database of molecular data of known phenotypes, the inference of the a... | 1. A method for stratifying a patient into a clinically relevant group, comprising with a computer performing the steps of:
obtaining datasets comprising one or more sets of molecular data from a patient sample; identifying the probability of an alteration within the one or more sets of molecular data in comparison to ... | The present invention relates to a method for stratifying a patient into a clinically relevant group comprising the identification of the probability of an alteration within one or more sets of molecular data from a patient sample in comparison to a database of molecular data of known phenotypes, the inference of the a... | 1,600 |
698 | 698 | 16,405,419 | 1,612 | A dental tool is provided which is capable of delivering an oligosaccharide containing composition to an oral biofilm, which can prevent and inhibit periodontal disease and in particular to devices and methods which mechanically and chemically disrupt biofilms formed by S. mutans. | 1. A dental tool comprising:
a substrate; and a composition comprising a complex carbohydrate, wherein said dental tool is selected from the group consisting of a floss, a tape, a floss pick, an interdental brush, and a pick, and wherein said complex carbohydrate is a β-glucan having a molecular weight of said β-glucan... | A dental tool is provided which is capable of delivering an oligosaccharide containing composition to an oral biofilm, which can prevent and inhibit periodontal disease and in particular to devices and methods which mechanically and chemically disrupt biofilms formed by S. mutans.1. A dental tool comprising:
a substrat... | 1,600 |
699 | 699 | 15,316,914 | 1,611 | Provided are ion complexes comprising treprostinil and an ion-exchange resin, pharmaceutical formulations based on such complexes, and methods of treating diseases and conditions using the ion complexes and pharmaceutical formulations. | 1. A composition comprising a) treprostinil or its derivative and b) an anion ion-exchange resin. 2. The composition of claim 1, wherein the treprostinil or its derivative form an ion complex with the anion exchange resin. 3. The composition of claim 1, wherein treprostinil is a free acid. 4. The composition of claim 1... | Provided are ion complexes comprising treprostinil and an ion-exchange resin, pharmaceutical formulations based on such complexes, and methods of treating diseases and conditions using the ion complexes and pharmaceutical formulations.1. A composition comprising a) treprostinil or its derivative and b) an anion ion-exc... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.